Christopher Lucci, MD
Public Health & General Preventive Medicine · Rockport, TXNPI 1447241955
Payments from drug & device makers
Across 1,098 payments — averaging $820.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$445K
- Corcept Therapeutics$315K
- Johnson & Johnson$120K
- Esperion Therapeutics, Inc.$9K
- AstraZeneca$8K
- Mannkind Corporation$655
- plus $3K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 452 | $444,810 |
| Corcept Therapeutics | 308 | $315,469 |
| Johnson & Johnson | 158 | $119,576 |
| Esperion Therapeutics, Inc. | 18 | $9,103 |
| AstraZeneca(2 entities) | 22 | $8,198 |
| Mannkind Corporation | 18 | $655 |
| Bayer | 28 | $521 |
| Xeris Pharmaceuticals, Inc. | 10 | $308 |
| Lilly USA, LLC | 12 | $267 |
| GSK | 2 | $200 |
| Tandem Diabetes Care, Inc. | 2 | $198 |
| Medtronic | 1 | $190 |
| Amgen | 9 | $178 |
| Novartis | 8 | $175 |
| Dexcom, Inc. | 6 | $128 |
| Recordati_rare_diseases_inc. | 4 | $124 |
| Arbor Pharmaceuticals, Inc. | 8 | $122 |
| Antares Pharma, Inc. | 4 | $78 |
| Amarin Pharma, Inc. | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Abbott | 2 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Nevro Corp. | 2 | $36 |
| Tactile Systems Technology Inc | 1 | $31 |
| BETA Bionics, Inc. | 2 | $27 |
| Aytu Biopharma, Inc. | 2 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $22 |
| AbbVie | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
How this compares
$900,829 in reported general payments places this provider in the 95th percentile of 41 public health & general preventive medicine providers in Texas.
See all public health & general preventive medicine providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other public health & general preventive medicine in Rockport
- Ryan GottfredsonJbsa Lackland$1.1M
- James SheehanFort Sam Houston$287K
- Barry DavisHouston$57K
- Richard LeconeyAlvin$24K
- Tyler CooperDallas$2K
- Prathima NagireddyFort Worth$2K
- John CarloDallas$1K
- Olivia IvyAustin$685
- Steven ClarkDallas$476
- Joseph CleaverDallas$331
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.